Canopy Growth Risk Quotient Down 76%, prior to 97% Stock Price Fall
Canadian company Canopy Growth attempted to enter US market via three acquisitions in anticipation of a change in federal drug laws.
RQ Score places Canopy Growth near the bottom of drug manufacturers
Auditors, stock exchange, and regulators question accounting treatment of these acquisitions, adding controversy over financial statements to regulatory uncertainty
Risk factors highlighted by RRX™
Stock Exchange Restrictions: “A variety of factors, including known and unknown risks, … include, without limitation, changes in laws, regulations and guidelines and our compliance with such laws, regulations and guidelines; … risks related to stock exchange restrictions; …” (10-K filed 2021-06-01)
Regulatory Interpretation: In addition, third parties with which we currently have business relationships, including auditors, banks, industry partners, customers and suppliers, may experience uncertainty associated with our U.S. strategy, including with respect to maintaining current or future relationships with us. While we believe that we comply with all applicable laws and regulations, there is a risk that our interpretation of laws, regulations, and guidelines, may differ from those of others.” (10-Q filed 2022-11-09)
Entering US market via three acquisitions raises investigation from Nasdaq and SEC
“The problem is that here we are at the close of 2023, and the deal is no closer to closing. … It’s gotten to the point that the company wants to house these investments in a special-purpose vehicle, Canopy USA –a move that the Nasdaq isn’t on board with, at least not for now.” 1
“Canopy Growth acknowledged the Nasdaq had raised a red flag about the company’s intention to consolidate Canopy USA’s financials with those of its parent company. In its Nov. 9 earnings release, Canopy Growth said it had received a letter on Nov. 3 in which the SEC essentially said it opposed Canopy’s solution to the Nasdaq issue.” 2
1 Cite: theglobeandmail.com
2 Cite: mjbizdaily.com
Highlighted Text Color Key:
- Extremely Concerning
- Very Concerning
- Somewhat Concerning
How would RRX™ help YOU analyze Canopy Growth’s risk?
C-suite & Board
Governance Strength Analysis
Identify gaps and optimize governance policies to align with market standards.
Real-Time Risk Monitoring
Track regulatory changes and governance-related events that could impact performance.
Competitive Benchmarking
Compare governance metrics against peers to maintain a competitive edge.
Corporate Advisors
Advanced Data Access
Leverage THEIA’s quantitative data to support client recommendations.
Scenario Analysis Tools
Run predictive scenarios to guide strategic decisions.
Impactful Reporting
Generate customized reports that validate your advisory insights.
Global Funds
Portfolio Risk Analysis
Understand governance-related risks across potential and existing investments.
ESG-Linked Metrics
Track governance data to align with ESG mandates.
Performance Benchmarking
Measure portfolio governance health against market leaders.
Regulators
Policy Impact Analysis
Assess the effectiveness of new and existing regulations.
Cross-Sector Data Integration
Access governance data across multiple industries.
Early Detection
Identify governance risks before they escalate.